Pulmonary hypertension reversed by blocking molecular pathway in rats

Pulmonary hypertension, a deadly form of high blood pressure that develops in the lungs, may be caused by an inflammation-producing molecular pathway that damages the inner lining of blood vessels, according to a new study by researchers at the Stanford University School of Medicine. The results, published in Science Translational Medicine, suggest that using medications to block this pathway could lead to the first-known cure for the disease, apart from lung transplantation...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Hypertension Source Type: news

Related Links:

Authors: Naranjo M, Lo KB, Mezue K, Rangaswami J Abstract Pulmonary hypertension is not uncommon in patients with renal disease and vice versa; therefore, influences treatments and outcomes. There is a large body of literature on pulmonary hypertension in patients with kidney disease, its prognostic implications, economic burden, and management strategies. However, the converse, namely the hemodynamic effects of pulmonary hypertension on kidney function (acute and chronic kidney injury) is less studied and described. There is also increasing interest in the effects of pulmonary hypertension on kidney transplant out...
Source: Current Cardiology Reviews - Category: Cardiology Tags: Curr Cardiol Rev Source Type: research
ConclusionsOur data indicate a trend toward improved survival over time of CTD-PAH and CTEPH patients treated at a Portuguese referral PH center. Earlier diagnosis, increasing use of parenteral prostanoids, and surgical treatment may further improve PH prognosis.ResumoIntroduçãoEste estudo tem como objetivo avaliar a sobrevivência a longo prazo em doentes com hipertensão arterial pulmonar (PAH) e hipertensão pulmonar tromboembólica crónica (CTEPH) seguidos num centro de tratamento.MétodosDoentes diagnosticados com PAH ou CTEPH entre janeiro 2005 e dezembro 2016 foram i...
Source: Revista Portuguesa de Cardiologia - Category: Cardiology Source Type: research
Patients with pulmonary hypertension (PH) due to chronic lung disease (Group 3 PH) have poor long-term outcomes. However, predictors of survival in Group 3 PH are not well described.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research
Pulmonary compromise has been shown to significantly contribute to nonrelapse mortality after hematopoietic stem cell transplantation (HSCT) [1-4]. The etiology of these pulmonary complications includes intrapulmonary causes of fibrosis and toxicities from treatment regimens or infections (ie, restrictive lung disease), graft-versus-host disease (GVHD) or bronchiolitis obliterans syndrome (BOS) (ie, obstructive lung disease), and vascular abnormalities (eg, pulmonary hypertension), as well as extrapulmonary causes, such as weakness or sclerodermatous GVHD.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Pulmonary compromise has been shown to significantly contribute to non-relapse mortality after hematopoietic stem cell transplantation (or HSCT).1-4 The etiology of these pulmonary complications includes intrapulmonary causes of fibrosis and toxicities from treatment regimens or infections (restrictive lung disease), graft-versus-host disease or bronchiolitis obliterans syndrome (obstructive lung disease), and vascular abnormalities (e.g. pulmonary hypertension), as well as extrapulmonary causes such as weakness or sclerodermatous GVHD.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
We present a case of living-donor lung transplantation for a 12-year-old girl with pulmonary hypertension after surgical repair of transposition of great arteries. Despite repairing the transposition of great arteries, her growth was severely restricted because of progressive pulmonary hypertension; thus, lung transplantation was discussed. Standard bilateral lobar transplantation seemed unfeasible due to oversized grafts, so we performed a single lobar transplantation. Unexpectedly, she developed complications and died 3 months postoperatively despite another emergent lobar transplantation. We discussed the challenges and...
Source: General Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Rationale: Severe cardiac dysfunction or severe pulmonary hypertension is a contraindication of liver transplantation (LT). Extracorporeal membrane oxygenation (ECMO) is an advanced therapy for severe lung and/or cardiocirculatory dysfunction or failure. The application of ECMO to patients during the LT perioperative period may help recipients with severe cardiac disease to maintain the heart function and alleviate the reperfusion syndrome. Patient concerns: A female liver recipient complained about weakness for 6 months. Diagnoses: The patient was diagnosed as hepatitis B virus (HBV)-related hepatic cirrhosis (MEL...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Neurofibromatosis type 1 (NF1), also known as von Recklinghausen disease, is a frequent autosomal dominant genetic disorder with a prevalence of 1 in 3000. Pulmonary hypertension (PH) associated with NF1 (PH-NF1) is a rare but severe complication of NF1 and is classified as Group 5 PH, defined as "PH with unclear and/or multifactorial mechanisms". A literature review in PubMed on the association between NF1 and PH identified 18 articles describing 31 cases. PH-NF1 was characterised by a female predominance, an advanced age at diagnosis, an association with parenchymal lung disease in two out of three cases and po...
Source: European Respiratory Review - Category: Respiratory Medicine Authors: Tags: Pulmonary vascular disease Group 5 Pulmonary Hypertension Source Type: research
Publication date: September 2018Source: The Annals of Thoracic Surgery, Volume 106, Issue 3Author(s): Mauricio A. Villavicencio, Andrea L. Axtell, Asishana Osho, Todd Astor, Nathalie Roy, Serguei Melnitchouk, David D’Alessandro, George Tolis, Yuval Raz, Isabel Neuringer, Thoralf M. SundtBackgroundDouble-lung transplantation (DLT) has better long-term outcomes compared with single-lung transplantation (SLT) in pulmonary fibrosis. However, controversy persists about whether older patients or patients with high lung allocation scores would benefit from DLT. Moreover, the degree of pulmonary hypertension in which SLT sho...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Conclusions: In patients with FIP, PVR is a significant contributor of 6MWD, independently from the extent of fibrosis on HRCT. These results strengthen both the rationale to use 6MWD as endpoint in FIP and to target APH with specific therapies.Respiration
Source: Respiration - Category: Respiratory Medicine Source Type: research
More News: Health | Hypertension | Lung Transplant | Pulmonary Hypertension | Science | Study | Transplants